News and presentations

News and presentations

Press Releases 


Cinclus Pharma appoints Jenni Björnulfson as Chief Financial Officer


Cinclus Pharma raises SEK 250 million for the continued development of a novel treatment against gastroesophageal reflux disease


Cinclus Pharma secures financing for preparation of Phase 2 study of X842



First clinical study successfully completed with X842, an innovative promising treatment for severe erosive GERD


Scientific publications


Phase 1 results presented at DDW, Washington, US, June 2018

The new P-CAB X482 was safe, tolerable and provided 24h intragastric control, after single oral doses in healthy volunteers


Crawley & Schmitt, JCOM, November 2000

How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs study.






Cinclus Pharma AB

Trädgårdsgatan 54

431 35 Mölndal


Kjell Andersson, CEO

+46 733 337 906

Peter Unge, CMO

+46 705 763 780

Copyright © All Rights Reserved